{{Drugbox
| verifiedrevid = 421882229
| IUPAC_name = 2-ethyl-3-propyloxirane-2-carboxamide
| image = Oxanamide.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 126-93-2
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 31365
| ChemSpiderID      = 29098

<!--Chemical data-->
| C=8 | H=15 | N=1 | O=2 
| molecular_weight = 157.21 g/mol
| smiles            = CCCC1C(O1)(CC)C(=O)N
| StdInChI          = 1S/C8H15NO2/c1-3-5-6-8(4-2,11-6)7(9)10/h6H,3-5H2,1-2H3,(H2,9,10)
| StdInChIKey       = WBLPIVIXQOFTPQ-UHFFFAOYSA-N

}}

'''Oxanamide''' ('''Quiactin''') is an [[anxiolytic]] and [[muscle relaxant]] which can produce [[sedative]] and [[hypnotic]] effects in sufficiently high doses.<ref>{{cite journal|title=Effects of oxanamide on the central nervous system |journal=Proceedings of the Society for Experimental Biology and Medicine |year=1960 |volume=103 |pages=101–3|pmid=14412594|last1=Kuhn|first1=WL|last2=Ketteler|first2=HJ|last3=Van Maanen|first3=EF}}</ref>  An uncontrolled trial on patients treated in a clinical [[gynecology]] practice published in 1959 found that oxanamide was efficacious in the treatment of anxiety resulting from [[premenstrual syndrome]], [[menopause]], and various other causes, with minimal sedation or other side effects.<ref>{{cite journal| author=Robert B. Woodhull |title=OXANAMIDE—Adjunctive Use of a New Tranquilizer in Gynecology| journal=California Medicine| year=1959 |volume=90 |issue=4 |pages=275–7 | pmid=13638840| pmc=1577644}}</ref>

== References ==
{{Reflist|2}}

{{Anxiolytics}}
{{Sedatives}}
{{Muscle relaxants}}

[[Category:Anxiolytics]]
[[Category:Sedatives]]
[[Category:Carboxamides]]
[[Category:Epoxides]]


{{musculoskeletal-drug-stub}}
{{nervous-system-drug-stub}}